Добірка наукової літератури з теми "Antimalaria- Drug"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Antimalaria- Drug".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Antimalaria- Drug"
Yousif, M. A., and A. A. Adeel. "Antimalarials prescribing patterns in Gezira state: precepts and practices." Eastern Mediterranean Health Journal 6, no. 5-6 (December 15, 2000): 939–47. http://dx.doi.org/10.26719/2000.6.5-6.939.
Повний текст джерелаUjuamala Uloma Ezeani, Penaere Theresa Osahon, and Michael Chukwudi Ezeani. "Pattern of anti-malarial drugs and artemether combination therapy adherence in an institution based medical centre, Nigeria." World Journal of Advanced Research and Reviews 8, no. 3 (December 30, 2020): 162–70. http://dx.doi.org/10.30574/wjarr.2020.8.3.0437.
Повний текст джерелаKocisko, David A., and Byron Caughey. "Mefloquine, an Antimalaria Drug with Antiprion Activity In Vitro, Lacks Activity In Vivo." Journal of Virology 80, no. 2 (January 15, 2006): 1044–46. http://dx.doi.org/10.1128/jvi.80.2.1044-1046.2006.
Повний текст джерелаGil, JP, and E. Gil Berglund. "CYP2C8 and antimalaria drug efficacy." Pharmacogenomics 8, no. 2 (February 2007): 187–98. http://dx.doi.org/10.2217/14622416.8.2.187.
Повний текст джерелаHede, K. "Antimalaria Drug Offers Antitumor Strategies." JNCI Journal of the National Cancer Institute 103, no. 20 (October 4, 2011): 1490–91. http://dx.doi.org/10.1093/jnci/djr423.
Повний текст джерелаBradbury, Jane. "Synthetic antimalaria drug enters clinical trials." Lancet Infectious Diseases 4, no. 10 (October 2004): 598. http://dx.doi.org/10.1016/s1473-3099(04)01161-2.
Повний текст джерелаLinda Ekawati, Linda Ekawati, Beta Achromi Nurohmah Beta Achromi Nurohmah, Jufrizal Syahri Jufrizal Syahri, and Bambang Purwono Bambang Purwono. "Substituted 3-styryl-2-pyrazoline Derivatives as an Antimalaria: Synthesis, in vitro Assay, Molecular Docking, Druglikeness Analysis and Admet Prediction." Sains Malaysiana 51, no. 10 (October 31, 2022): 3215–36. http://dx.doi.org/10.17576/jsm-2022-5110-09.
Повний текст джерелаPeter, Sijongesonke, and Blessing Atim Aderibigbe. "Ferrocene-Based Compounds with Antimalaria/Anticancer Activity." Molecules 24, no. 19 (October 7, 2019): 3604. http://dx.doi.org/10.3390/molecules24193604.
Повний текст джерелаMuhaimin, Muhaimin, Yusnaidar Yusnaidar, and Hilda Amanda. "Antimalaria Activity of Macaranga Gigantea Leaves Extracts." Journal of The Indonesian Society of Integrated Chemistry 10, no. 2 (April 6, 2019): 23–32. http://dx.doi.org/10.22437/jisic.v10i2.6581.
Повний текст джерелаTahir, Iqmal, Mudasir Mudasir, Irza Yulistia, and Mustofa Mustofa. "QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP ANALYSIS (QSAR) OF VINCADIFFORMINE ANALOGUES AS THE ANTIPLASMODIAL COMPOUNDS OF THE CHLOROQUINOSENSIBLE STRAIN." Indonesian Journal of Chemistry 5, no. 3 (June 15, 2010): 255–60. http://dx.doi.org/10.22146/ijc.21800.
Повний текст джерелаДисертації з теми "Antimalaria- Drug"
Kumar, Hirdesh. "Identification of vaccine and drug targets against malaria." Thesis, IIT Delhi, 2016. http://localhost:8080/xmlui/handle/12345678/7008.
Повний текст джерелаPongtavornpinyo, Wirichada. "Mathematical modelling of antimalarial drug resistance." Thesis, University of Liverpool, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.428249.
Повний текст джерелаMatthews, H. "Accelerating antimalarial drug discovery through repositioning." Thesis, University of Salford, 2013. http://usir.salford.ac.uk/36885/.
Повний текст джерелаSumanadasa, Subathdrage Dulangi Madushika. "Investigation of Novel Antimalarial Agents and Novel Target Identification Approaches." Thesis, Griffith University, 2015. http://hdl.handle.net/10072/367036.
Повний текст джерелаThesis (PhD Doctorate)
Doctor of Philosophy (PhD)
School of Biomolecular and Physical Sciences
Science, Environment, Engineering and Technology
Full Text
Uhlemann, Anne-Catrin. "Plasmodium falciparum transporters as antimalarial drug targets." Thesis, St George's, University of London, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.559278.
Повний текст джерелаPrice, K. E. "Antimalarial drug discovery : exploring the MEP pathway." Thesis, University of Liverpool, 2016. http://livrepository.liverpool.ac.uk/3005814/.
Повний текст джерелаSilal, Sheetal Prakash. "A simulation model of antimalarial drug resistance." Master's thesis, University of Cape Town, 2009. http://hdl.handle.net/11427/9003.
Повний текст джерелаMalaria ranks among the world's most important tropical parasitic diseases with world prevalence figures between 350 and 550 million clinical cases per annum. [WHO, 2008a] 'Treatment and prevention of malaria places a considerable burden on struggling economies where the disease is rampant. Research in malaria does not stop as the change in response to antimalarial drug treatment requires the development of new drugs and innovation in the use of old drugs. This thesis focused on building a model of the spread of resistance to Sulfadoxine/Pyrimethamine (SP) in a setting where both SP and SP in artemisinin-based combination therapy (ACT) are the first line therapies for malaria. The model itself is suitable to any low transmission setting where antimalarial drug resistance exists but the country of choice in this modeling exercise was Mozambique. The model was calibrated using parameters specific to the malaria situation in Mozambique. This model was intended to be used to aid decision making in countries where antimalarial drug resistance exists to help prevent resistance spreading to such an extent that drugs lose their usefulness in curing malaria. The modeling technique of choice was differential equation modeling; a simulation technique that falls under the System Dynamics banner in the Operations Research armamentarium. It is a technique that allowed the modeling of stocks and flows that represent different stages or groupings in the disease process and the rate of movement between these stages respectively. The base model that was built allowed infected individuals to become infectious, to be treated with SP or ACT and to be sensitive to or fail treatment. Individuals were allowed a period of temporary immunity where they would not be reinfected until the residual SP had been eliminated from their bloodstream. The base model was then further developed to include the pharmacokinetic properties of SP where individuals were allowed to be reinfected with certain strains of infection given the level of residual drug in their bloodstream after their current infection had been cleared. The models used in this thesis were built with idea of expanding on previous models and using available data to improve parameter estimates. The model at its core is similar to the resistance model used in Koella and Antia [2003] where differential equation modeling was used to monitor a population as it became infected with a sensitive or resistant infection and then University of Cape Town recovered. The inclusion in the model of the PK component was derived from Prudhomme-O'Meara et al. [2006] where individuals could be reinfected depending on the residual drug in their bloodstream. Rather than modeling simply sensitive and resistant infections, mutations categories were used as was the case in Watkins et al. [2005] population genetics model. The use of mutation categories allowed one to use parameters specific to these categories rather than the sensitive/resistant stratification and this is particularly relevant in Mozambique where all mutation categories still exhibit some degree of sensitivity to treatment i.e. total resistance has not yet developed for any particular mutation category. The last adaptation of the model was to use gametocyte information directly to determine human infectiousness rather than through using a gametocyte switching rate (constant multiplier used to convert parasite density to gametocyte density) as was done in Pongtavompinyo [2006]. The models developed in this thesis found that the existing vector control and drug policy in Mozambique had the major effect of decreasing total prevalence of malaria by approximately 70% in the 11 year period. The distribution of Res3 (presence of DHFR triple) and Res5 (presence of DHFR triple and DHPS double) infections changed over the 11 year period with Res3 infections initially increasing and then decreasing while Res5 infections started low and increased to overtake Res3 infections. The timing of the change in this composition of infection corresponds with the introduction of ACT and thus it appears that the use of ACT prompted the increased prevalence of quintuple parasites over DHFR triple and sensitive parasites. The total number of failures decreased substantially after the introduction of ACT to 17% of its previous level. The results of the base model corresponded with the observed data from the SEACAT study in terms of the magnitude and the trends of the impact of the change to ACT policy, but underestimated the impact of the vector control strategies compared to rapid effect noted in Sharp et al. [2007]. The Scenario testing of the base model showed that vector control is an effective strategy to reduce prevalence and that it is sensitive to the time at which the control is started as it decreased prevalence very gradually. The Scenario testing of the base model also showed that the introduction of ACT in Mozambique had a greater impact on reducing prevalence and that the start time of the ACT strategy did not decrease the effect on prevalence though earlier start times decreased the total number of resistance cases. The ratio of Res5 to Res3 infections increased faster when ACT was the treatment policy than when SP was the policy. Thus higher values of this ratio are associated with ACT being the treatment strategy in place. Thus differential equation modeling is an effective modeling tool to capture the spread of disease and to test the effects of policy interventions as it allows one to assess these effects on populations and averages out individual-level intricacies to better inform policy decisions.
Kay, Katherine. "Pharmacological modelling to investigate antimalarial drug treatment." Thesis, University of Liverpool, 2013. http://livrepository.liverpool.ac.uk/12413/.
Повний текст джерелаAl, Helal Mohammad Abdullah. "Pharmacodynamics of antimalarial endoperoxide drugs." Thesis, University of Liverpool, 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.526822.
Повний текст джерелаBlake, Lynn Dong. "Antimalarial Exoerythrocytic Stage Drug Discovery and Resistance Studies." Scholar Commons, 2016. http://scholarcommons.usf.edu/etd/6182.
Повний текст джерелаКниги з теми "Antimalaria- Drug"
Silikas, Nikolaos. Rational drug design of protoberberine antimalarials. Manchester: University of Manchester, 1995.
Знайти повний текст джерелаCsizmadia, Emanuel. Antimalarial drugs: Costs, safety and efficacy. New York: Nova Biomedical Books, 2009.
Знайти повний текст джерелаEmanuel, Csizmadia, and Kalnoky Istvan, eds. Antimalarial drugs: Costs, safety, and efficacy. Hauppauge, NY: Nova Science, 2009.
Знайти повний текст джерелаLi, Qigui. Antimalarial drugs: Age of the artemisinins. Hauppauge, N.Y: Nova Science, 2010.
Знайти повний текст джерелаM, Gomes, Pang L, and World Health Organization, eds. Interventions to improve antimalarial use. Geneva: World Health Organization, 1998.
Знайти повний текст джерелаOrganization, World Health, ed. A Practical handbook on the pharmacovigilance of antimalarial medicines. Geneva, Switzerland: World Health Organization, 2008.
Знайти повний текст джерелаKiang, Tony K. L., Kyle John Wilby, and Mary H. H. Ensom. Clinical Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antimalarials. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-10527-7.
Повний текст джерелаStaines, Henry M. Treatment and Prevention of Malaria: Antimalarial Drug Chemistry, Action and Use. Basel: Springer Basel, 2012.
Знайти повний текст джерелаPeters, Wallace. Chemotherapy and drug resistance in malaria. 2nd ed. London: Academic Press, 1987.
Знайти повний текст джерелаCentral Council for Research in Unani Medicine (India), ed. Potential antimalarial herbal drugs from South Eastern India: Bihar and Orissa states. New Delhi: Central Council for Research in Unani Medicine, Ministry of Health & Family Welfare, Govt. of India, 2000.
Знайти повний текст джерелаЧастини книг з теми "Antimalaria- Drug"
Adedeji, Waheed A., Tunde Balogun, Fatai A. Fehintola, and Gene D. Morse. "Drug-Drug Interactions of Antimalarial Drugs." In Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions, 503–14. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-72416-4_12.
Повний текст джерелаShah, Naman K., and Neena Valecha. "Antimalarial drug resistance." In Advances in Malaria Research, 383–407. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2016. http://dx.doi.org/10.1002/9781118493816.ch14.
Повний текст джерелаKiang, Tony K. L., Kyle John Wilby, and Mary H. H. Ensom. "Drug Interaction Potential of Antimalarial Drugs Based on Known Metabolic Properties of Antimalarials." In Clinical Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antimalarials, 17–25. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-10527-7_3.
Повний текст джерелаPile, Kevin D., Garry G. Graham, Constance H. Katelaris, and Richard O. Day. "Antimalarial Drugs." In Compendium of Inflammatory Diseases, 97–101. Basel: Springer Basel, 2016. http://dx.doi.org/10.1007/978-3-7643-8550-7_9.
Повний текст джерелаPile, Kevin, Garry G. Graham, Constance H. Katelaris, and Richard O. Day. "Antimalarial Drugs." In Encyclopedia of Inflammatory Diseases, 1–6. Basel: Springer Basel, 2013. http://dx.doi.org/10.1007/978-3-0348-0620-6_9-1.
Повний текст джерелаParikh, Sunil, Ming-Na Tina Lee, and Francesca T. Aweeka. "Antimalarial Agents." In Drug Interactions in Infectious Diseases, 561–79. Totowa, NJ: Humana Press, 2011. http://dx.doi.org/10.1007/978-1-61779-213-7_16.
Повний текст джерелаTull, Thomas, and Mark Goodfield. "Antimalarials." In Handbook of Systemic Drug Treatment in Dermatology, 61–66. 3rd ed. London: CRC Press, 2022. http://dx.doi.org/10.1201/9781003016786-7.
Повний текст джерелаMeunier, Bernard. "Towards Antimalarial Hybrid Drugs." In Polypharmacology in Drug Discovery, 423–39. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2012. http://dx.doi.org/10.1002/9781118098141.ch21.
Повний текст джерелаRosenthal, Philip J. "Antimalarial Drug Resistance: Clinical Perspectives." In Antimicrobial Drug Resistance, 1077–90. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-595-8_27.
Повний текст джерелаBiagini, Giancarlo A., Patrick G. Bray, and Stephen A. Ward. "Mechanisms of Antimalarial Drug Resistance." In Antimicrobial Drug Resistance, 561–74. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-180-2_40.
Повний текст джерелаТези доповідей конференцій з теми "Antimalaria- Drug"
Kalogera, Eleftheria, Debarshi Roy, Ashwani Khurana, Susmita Mondal, Xiaoping He, Sean C. Dowdy, and Viji Shridhar. "Abstract 261: Quinacrine in endometrial cancer: repurposing an old antimalarial drug." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-261.
Повний текст джерелаKapelle, Imanuel Berly Delvis, Shielda Natalia Joris, Natelda Rosaldiah Timisela, Esther Kembauw, Marthinus Johanes Saptenno, and Fransisca Kissya. "Product diversification of katang-katang leaf (Ipomoea pescaprae) as an antimalarial drug." In THE 7TH INTERNATIONAL CONFERENCE ON BASIC SCIENCES 2021 (ICBS 2021). AIP Publishing, 2023. http://dx.doi.org/10.1063/5.0113993.
Повний текст джерелаMegantara, Sandra, Jutti Levita, and Slamet I. Surantaatmadja. "In Silico Study of Andrographolide as Protease Inhibitors for Antimalarial Drug Discovery." In 3rd International Conference on Computation for Science and Technology (ICCST-3). Paris, France: Atlantis Press, 2015. http://dx.doi.org/10.2991/iccst-15.2015.8.
Повний текст джерелаRodriguez Henriquez, P., F. J. Reyes-Muciño, and L. M. Amezcua-Guerra. "AB0393 Electrocardiographic disturbances in patients with rheumatoid arthritis using antimalarial drugs." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.5668.
Повний текст джерелаJulianto, Tatang Shabur, Rizki Ariadi Tama, and Amri Setyawati. "Synthesis of aryl amino alcohol derivate from turpentine oil as a potential antimalarial drug." In 3RD INTERNATIONAL CONFERENCE ON CHEMISTRY, CHEMICAL PROCESS AND ENGINEERING (IC3PE). AIP Publishing, 2021. http://dx.doi.org/10.1063/5.0062834.
Повний текст джерелаAbbas, Jamilah, Nina Artanti, Andini Sundowo, Indah Dwiatmi Dewijanti, Muhammad Hanafi, Lisa, and Din Syafrudin. "Targetting the hemozoin synthesis pathway for antimalarial drug and detected by TEM (Transmission electron microscope)." In PROCEEDINGS OF THE 3RD INTERNATIONAL SYMPOSIUM ON APPLIED CHEMISTRY 2017. Author(s), 2017. http://dx.doi.org/10.1063/1.5011930.
Повний текст джерелаRiesco Barcena, C., S. Leal Rodríguez, ME Acosta de la Vega, E. Grau García, C. Pávez Perales, AV Huaylla Quispe, M. De la Rubia, et al. "PO.8.175 Antimalarial drugs and electrocardiographic alterations in patients with systemic lupus erythematosus." In 13th European Lupus Meeting, Stockholm (October 5–8, 2022). Lupus Foundation of America, 2022. http://dx.doi.org/10.1136/lupus-2022-elm2022.194.
Повний текст джерелаFasinu, Pius. "The metabolism of the 8-aminoquinolines in relation to hemolytic toxicity: exploring current understanding for future antimalarial drug discovery." In ASPET 2023 Annual Meeting Abstracts. American Society for Pharmacology and Experimental Therapeutics, 2023. http://dx.doi.org/10.1124/jpet.122.140510.
Повний текст джерелаTisnerat, Camille, Jérémy Schneider, René Pemha, Céline Damiani, Patrice Agnamey, Catherine Mullié, Anne Totet, Alexandra Dassonville-Klimpt, and Pascal Sonnet. "Synthesis and biological evaluation of new enantiopure 4-aminoalcohol-quinoline and -fluorene hybrids as antimalarial drugs." In 6th International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2020. http://dx.doi.org/10.3390/ecmc2020-07397.
Повний текст джерела"Virtual Screening the Interaction of Various Compound from Indonesian Plants with the HGXPRT Enzyme to Find a Novel Antimalarial Drug." In The 3rd International Conference on Life Sciences and Biotechnology. Galaxy Science, 2021. http://dx.doi.org/10.11594/nstp.2021.0805.
Повний текст джерелаЗвіти організацій з теми "Antimalaria- Drug"
Dhawan, B. N. Evaluation of New Antimalarials. Development of New Antimalarial Drugs. Fort Belvoir, VA: Defense Technical Information Center, September 1991. http://dx.doi.org/10.21236/ada242409.
Повний текст джерелаTesfaselassie, Elias. Antimalarial Drug Discovery using Triazoles to Overcome Chloroquine Resistance. Portland State University Library, January 2000. http://dx.doi.org/10.15760/etd.2503.
Повний текст джерелаHodson Shirley, Cheryl. The Antimalarial Activity of PL74: A Pyridine-Based Drug Candidate. Portland State University Library, January 2000. http://dx.doi.org/10.15760/etd.1820.
Повний текст джерелаBasagoitia, Andrea. Do home- or community-based programmes for treating malaria improve health outcomes? SUPPORT, 2017. http://dx.doi.org/10.30846/170313.
Повний текст джерелаAvery, Mitchell A. Directed Synthesis of New Antimalarials Using Computer Aided Drug Design. Fort Belvoir, VA: Defense Technical Information Center, October 1995. http://dx.doi.org/10.21236/ada303867.
Повний текст джерелаAvery, Mitchell A. Directed Synthesis of New Antimalarials using Computer Aided Drug Design. Fort Belvoir, VA: Defense Technical Information Center, October 1995. http://dx.doi.org/10.21236/ada304919.
Повний текст джерелаParshikov, I. A., C. E. Hernandes-Luna, and E. I. Zaraisky. Microbial transformation of the antimalarial and anticancer drug artemisinin by white-rot basidiomycetes. Global Science Publications, 2018. http://dx.doi.org/10.18411/0972-3005_n4.
Повний текст джерелаAvery, Mitchell A. Drug Development of the Antimalarial Agent Artemisinin: Total Synthesis, Analog Synthesis, and Structure-Activity Relationship Studies. Fort Belvoir, VA: Defense Technical Information Center, August 1990. http://dx.doi.org/10.21236/adb152141.
Повний текст джерелаLiebman, Katherine. New 4-Aminoquinoline Compounds to Reverse Drug Resistance in P. falciparum Malaria, and a Survey of Early European Antimalarial Treatments. Portland State University Library, January 2000. http://dx.doi.org/10.15760/etd.2112.
Повний текст джерела